Study on Remote Opioid Monitoring

Summary#

The Remote Opioid Monitoring Act of 2025 would create a federal study requirement; it does not amend another law. Its stated goal is to examine the effects of remote monitoring for people prescribed opioids. This is an introduced bill, not law, so whether it will take effect is uncertain.

  • The Comptroller General must conduct the study and send a report to specified House and Senate committees within 18 months after the bill becomes law.
  • The report must assess scientific evidence about effectiveness, individual outcomes and possible cost savings, comparing people who are monitored with those who are not.
  • The report must examine how common remote monitoring is in the United States and other countries.
  • The report must recommend ways to improve availability, access and coverage, including possible changes to federal health care programs. If the Comptroller General considers it appropriate, the report must also identify groups that may benefit most.

What it means for you#

  • People prescribed opioids: The bill would not require you to use remote monitoring or change your prescription, treatment, or coverage. It requires a study and recommendations.
  • Health care providers and insurers: The bill creates no direct requirement for you to monitor patients or provide or cover monitoring.
  • The Comptroller General: Must complete the study and report within the stated deadline.
  • Congress: The named committees would receive the report. The bill does not require them to adopt its recommendations.

Money#

No cost estimate is provided in the bill or supplied material.

  • The bill requires the Comptroller General to conduct a study, but does not state how much staff time or money it will require.
  • It does not appropriate funds, create a monitoring benefit, or require federal health care programs to pay for monitoring.

What is unclear#

  • The bill does not define “remote monitoring” or specify which types of monitoring the study must examine.
  • It does not set out the study methods or how the Comptroller General should measure individual outcomes or possible cost savings.
  • The recommendations must address availability, access and coverage, but the bill does not say what changes the report must recommend.
  • The bill does not require agencies or Congress to act on the recommendations.

Case for#

  • A possible argument for the bill is that decision-makers need evidence about whether remote monitoring helps people prescribed opioids and what outcomes it is associated with.
  • Comparing monitored and unmonitored patients could help assess possible benefits and costs rather than assuming monitoring works.
  • Looking at use in other countries could give Congress information about how common the practice is elsewhere.
  • Recommendations could identify ways to improve access or coverage if the study finds a basis for doing so.

Case against#

  • One concern is that the bill requires a study but does not require any later action, so its recommendations may not change access or coverage.
  • The bill does not define remote monitoring or specify study methods, leaving important details to the study itself.
  • The study will require staff time and resources, but the bill provides no cost estimate or funding amount.
  • The report is due up to 18 months after enactment, so it would not provide immediate changes to care or coverage.